FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386370844> ?p ?o ?g. }

• W4386370844 endingPage "1090" @default.
• W4386370844 startingPage "1090" @default.
• W4386370844 abstract "<ns4:p><ns4:bold>Background: </ns4:bold>Cancer and inflammation are strongly connected; tumor growth and spread are also greatly influenced by inflammation. Nitrogen-based heterocycle analogs are excellent suppliers of pharmaceuticals. Quaternary rings play a bigger role in drug development as bioactive scaffolds. For improved tolerance and synergistic benefits, heterocyclic nitrogen rings are present in many anticancer medications. Understanding how to bind to the EGFR and its prospective impacts on cancer cells, expect to construct new heterocyclic compounds that may help produce potent anticancer medicines with a high safety profile.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>Novel 1,3-diazetidin-2-one derivatives were designed, synthesized from mefenamic acid, and their cytotoxic activity against a lung cancer cell line (A549) was initially tested in vitro. These compounds were anchored to the crystal structure of the epidermal growth factor receptor (PDB code 1M17) in a molecular docking study to determine their binding affinity at the active site. The newly synthesized derivatives were verified and confirmed by elemental analysis and spectroscopic data (FT-IR, <ns4:sup>1</ns4:sup>H-NMR, and <ns4:sup>13</ns4:sup>C-NMR). In addition, physicochemical, drug-like, and toxicological predictions were performed for these derivatives.</ns4:p><ns4:p> <ns4:bold>Results: </ns4:bold>Based on a molecular docking study, all compounds (M4a-e) demonstrated superior PLPfitness (84.70, 85.89, 91.90, 88.61, and 92.77, respectively) to erlotinib (76.20). The anti-proliferation evaluation of the A549 cell line revealed that compounds M4c and M4e had exceptional and promising anti-proliferative activity on this cell line to treat lung cancer, with IC50 values of 1.75 µm and 2.05 µm at 72 hours, respectively, making them significantly more active than the reference erlotinib, which had an IC50 value of 11.5 µm at 72 hours.</ns4:p><ns4:p> <ns4:bold>Conclusions: </ns4:bold>The cytotoxicity investigation and the molecular docking study showed a robust association with the novel compounds (M4a-e). Suggest a comprehensive pharmacological survey to understand how these newly created chemicals combat cancer fully.</ns4:p>" @default.
• W4386370844 created "2023-09-02" @default.
• W4386370844 creator A5063985849 @default.
• W4386370844 creator A5078706267 @default.
• W4386370844 creator A5092729625 @default.
• W4386370844 date "2023-09-01" @default.
• W4386370844 modified "2023-10-16" @default.
• W4386370844 title "In silico molecular docking, ADME study and synthesis of new 1,3-diazetidin-2-one derivatives with high anti-proliferative activity" @default.
• W4386370844 cites W2339810942 @default.
• W4386370844 cites W2604783384 @default.
• W4386370844 cites W2795006397 @default.
• W4386370844 cites W2912993305 @default.
• W4386370844 cites W2944633487 @default.
• W4386370844 cites W2951620617 @default.
• W4386370844 cites W3016135104 @default.
• W4386370844 cites W3120125360 @default.
• W4386370844 cites W3161599862 @default.
• W4386370844 cites W3205681413 @default.
• W4386370844 cites W4280517461 @default.
• W4386370844 cites W4283763719 @default.
• W4386370844 cites W4289323252 @default.
• W4386370844 cites W4318686650 @default.
• W4386370844 doi "https://doi.org/10.12688/f1000research.138510.1" @default.
• W4386370844 hasPublicationYear "2023" @default.
• W4386370844 type Work @default.
• W4386370844 citedByCount "0" @default.
• W4386370844 crossrefType "journal-article" @default.
• W4386370844 hasAuthorship W4386370844A5063985849 @default.
• W4386370844 hasAuthorship W4386370844A5078706267 @default.
• W4386370844 hasAuthorship W4386370844A5092729625 @default.
• W4386370844 hasBestOaLocation W43863708441 @default.
• W4386370844 hasConcept C185592680 @default.
• W4386370844 hasConcept C2780035454 @default.
• W4386370844 hasConcept C69366308 @default.
• W4386370844 hasConcept C71240020 @default.
• W4386370844 hasConcept C86803240 @default.
• W4386370844 hasConcept C98274493 @default.
• W4386370844 hasConceptScore W4386370844C185592680 @default.
• W4386370844 hasConceptScore W4386370844C2780035454 @default.
• W4386370844 hasConceptScore W4386370844C69366308 @default.
• W4386370844 hasConceptScore W4386370844C71240020 @default.
• W4386370844 hasConceptScore W4386370844C86803240 @default.
• W4386370844 hasConceptScore W4386370844C98274493 @default.
• W4386370844 hasLocation W43863708441 @default.
• W4386370844 hasOpenAccess W4386370844 @default.
• W4386370844 hasPrimaryLocation W43863708441 @default.
• W4386370844 hasRelatedWork W188266097 @default.
• W4386370844 hasRelatedWork W2036965660 @default.
• W4386370844 hasRelatedWork W2111483198 @default.
• W4386370844 hasRelatedWork W2322979026 @default.
• W4386370844 hasRelatedWork W2681933021 @default.
• W4386370844 hasRelatedWork W2906353975 @default.
• W4386370844 hasRelatedWork W2943083791 @default.
• W4386370844 hasRelatedWork W2997518748 @default.
• W4386370844 hasRelatedWork W3024433273 @default.
• W4386370844 hasRelatedWork W3043692578 @default.
• W4386370844 hasVolume "12" @default.
• W4386370844 isParatext "false" @default.
• W4386370844 isRetracted "false" @default.
• W4386370844 workType "article" @default.